SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today announced that it has commenced promotion of GLUMETZA® (metformin hydrochloride extended release tablets), a once-daily, extended-release formulation of metformin that incorporates patented drug delivery technology and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Santarus signed a promotion agreement with Depomed, Inc. in July 2008 granting Santarus exclusive rights to promote GLUMETZA in the U.S.
